ABSTRACT
Oxime-based molecules are used for the treatment of patients to reactivate acetylcholinesterase (AChE) function after organophosphate intoxication. However, their efficacy is limited by low penetration through the blood-brain barrier and fast elimination. In this work, the cucurbit[7]uril (CB[7]) carrier was used for the encapsulation of the clinical agent asoxime to enhance brain bioavailability and the treatment window. We present a pharmacokinetic study of asoxime and the asoxime-CB[7] complex in an in vivo mouse model. Ultrahigh-performance liquid chromatography with electrospray ionization-mass spectrometry detection was developed to determine asoxime and CB[7] in biological fluids and tissues after thorough optimization of chromatographic conditions. The dihydroxypropane-silica stationary phase using hydrophilic interaction liquid chromatography conditions provided the best chromatographic performance. The final method was validated and applied for the pharmacokinetic study of mouse plasma, urine, bile, liver, kidney, and brain samples at different times after administration of asoxime and the asoxime-CB[7] complex. The results showed a greater than 3-fold increase in the area under the curve (AUC) in the brain for asoxime administered as a complex with CB[7] relative to that for the administration of asoxime alone. The effectiveness of the treatment strategy was evaluated using a reactivation study and a functional observatory battery. Protection of brain AChE activity is crucial for saving human lives or reducing the consequences of poisoning. The asoxime administered as a complex increased the brain activity by approximately 30% compared to that with atropine alone. CB[7] coadministration improved the AChE activity by 11%, which agrees with the higher asoxime AUC assessed in the pharmacokinetic study.
Subject(s)
Bridged-Ring Compounds/chemistry , Cholinesterase Reactivators/administration & dosage , Drug Carriers/chemistry , Imidazoles/chemistry , Organophosphate Poisoning/drug therapy , Oximes/pharmacokinetics , Pyridinium Compounds/pharmacokinetics , Acetylcholinesterase/metabolism , Animals , Area Under Curve , Blood-Brain Barrier/metabolism , Cholinesterase Inhibitors/administration & dosage , Cholinesterase Inhibitors/toxicity , Cholinesterase Reactivators/pharmacokinetics , Chromatography, High Pressure Liquid , Disease Models, Animal , Enzyme Assays , Humans , Hydrophobic and Hydrophilic Interactions , Mass Spectrometry , Mice , Oximes/administration & dosage , Pyridinium Compounds/administration & dosage , Sarin/administration & dosage , Sarin/toxicityABSTRACT
Past assassinations and terrorist attacks demonstrate the need for a more effective antidote against nerve agents and other organophosphates (OP) that cause brain damage through inhibition of acetylcholinesterase (AChE). Our lab has invented a platform of phenoxyalkyl pyridinium oximes (US patent 9,277,937) that demonstrate the ability to cross the blood-brain barrier in in vivo rat tests with a sarin surrogate nitrophenyl isopropyl methylphosphonate (NIMP) and provide evidence of brain penetration by reducing cessation time of seizure-like behaviors, accumulation of glial fibrillary acidic protein (GFAP), and hippocampal neuropathology, as opposed to the currently approved oxime, 2-pyridine aldoxime methyl chloride (2-PAM). Using two of the novel oximes (Oximes 1 and 20), this project examined whether gene expression changes might help explain this protection. Expression changes in the piriform cortex were examined using polymerase chain reaction arrays for inflammatory cytokines and receptors. The hippocampus was examined via quantitative polymerase chain reaction for the expression of immediate-early genes involved in brain repair (Bdnf), increasing neurotoxicity (Fos), and apoptosis control (Jdp2, Bcl2l1, Bcl2l11). In the piriform cortex, NIMP significantly stimulated expression for the macrophage inflammatory proteins CCL4, IL-1A, and IL-1B. Oxime 20 by itself elicited the most changes. When it was given therapeutically post-NIMP, the largest change occurred: a 310-fold repression of the inflammatory cytokine, CCL12. In the hippocampus, NIMP increased the expression of the neurotoxicity marker Fos and decreased the expression of neuroprotective Bdnf and antiapoptotic Bcl2l1. Compared with 2-PAM, Oxime 20 stimulated Bcl2l1 expression more and returned expression closer to the vehicle control values.
Subject(s)
Acetylcholinesterase , Brain/metabolism , Cholinesterase Reactivators , Gene Expression Regulation/drug effects , Oximes , Sarin/toxicity , Acetylcholinesterase/metabolism , Animals , Brain/pathology , Cholinesterase Reactivators/chemistry , Cholinesterase Reactivators/pharmacokinetics , Cholinesterase Reactivators/pharmacology , GPI-Linked Proteins/antagonists & inhibitors , GPI-Linked Proteins/metabolism , Male , Oximes/chemistry , Oximes/pharmacokinetics , Oximes/pharmacology , Rats , Rats, Sprague-DawleyABSTRACT
Nerve agent exposure is generally treated by an antidote formulation composed of a muscarinic antagonist, atropine sulfate (ATR), and a reactivator of acetylcholinesterase (AChE) such as pralidoxime, obidoxime (OBI), methoxime, trimedoxime or HI-6 and an anticonvulsant. Organophosphates (OPs) irreversibly inhibit AChE, the enzyme responsible for termination of acetylcholine signal transduction. Inhibition of AChE leads to overstimulation of the central and peripheral nervous system with convulsive seizures, respiratory distress and death as result. The present study evaluated the efficacy and pharmacokinetics (PK) of ATR/OBI following exposure to two different VX dose levels. The PK of ATR and OBI administered either as a single drug, combined treatment but separately injected, or administered as the ATR/OBI co-formulation, was determined in plasma of naïve guinea pigs and found to be similar for all formulations. Following subcutaneous VX exposure, ATR/OBI-treated animals showed significant improvement in survival rate and progression of clinical signs compared to untreated animals. Moreover, AChE activity after VX exposure in both blood and brain tissue was significantly higher in ATR/OBI-treated animals compared to vehicle-treated control. In conclusion, ATR/OBI has been proven to be efficacious against exposure to VX and there were no PK interactions between ATR and OBI when administered as a co-formulation.
Subject(s)
Atropine , Chemical Warfare Agents/toxicity , Cholinesterase Inhibitors/toxicity , Cholinesterase Reactivators , Muscarinic Antagonists , Obidoxime Chloride , Organothiophosphorus Compounds/toxicity , Acetylcholinesterase/blood , Acetylcholinesterase/metabolism , Animals , Atropine/blood , Atropine/pharmacokinetics , Atropine/therapeutic use , Brain/metabolism , Cholinesterase Reactivators/blood , Cholinesterase Reactivators/pharmacokinetics , Cholinesterase Reactivators/therapeutic use , Disease Models, Animal , Drug Combinations , Guinea Pigs , Male , Muscarinic Antagonists/blood , Muscarinic Antagonists/pharmacokinetics , Muscarinic Antagonists/therapeutic use , Obidoxime Chloride/blood , Obidoxime Chloride/pharmacokinetics , Obidoxime Chloride/therapeutic use , Treatment OutcomeABSTRACT
The nanotechnological approach is an innovative strategy of high potential to achieve reactivation of organophosphorus-inhibited acetylcholinesterase in central nervous system. It was previously shown that pralidoxime chloride-loaded solid lipid nanoparticles (2-PAM-SLNs) are able to protect the brain against pesticide (paraoxon) central toxicity. In the present work, we increased brain AChE reactivation efficacy by PEGylation of 2-PAM-SLNs using PEG-lipid N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, sodium salt) (DSPE-PEG2000) as a surface-modifier of SLNs. To perform pharmacokinetic study, a simple, sensitive (LLOQ 1.0 ng/mL) high-performance liquid chromatography tandem mass spectrometry with atmospheric pressure chemical ionization by multiple reaction monitoring mode (HPLC-APCI-MS) was developed. The method was compared to mass spectrometry with electrospray ionization. The method was validated for linearity, accuracy, precision, extraction recovery, matrix effect and stability. Acetophenone oxime was used as the internal standard for the quantification of 2-PAM in rat plasma and brain tissue after intravenous administration. 2-PAM-DSPE-PEG2000-SLNs of mean size about 80 nm (PDI = 0.26), zeta-potential of -55 mV and of high in vitro stability, prolonged the elimination phase of 2-PAM from the bloodstream more than 3 times compared to free 2-PAM. An increase in reactivation of POX-inhibited human brain acetylcholinesterase up to 36.08 ± 4.3 % after intravenous administration of 2-PAM-DSPE-PEG2000-SLNs (dose of 2-PAM is 5 mg/kg) was achieved. The result is one of the first examples where this level of brain acetylcholinesterase reactivation was achieved. Thus, the implementation of different approaches for targeting and modifying nanoparticles' surface gives hope for improving the antidotal treatment of organophosphorus poisoning by marketed reactivators.
Subject(s)
Antidotes/administration & dosage , Cholinesterase Inhibitors/toxicity , Cholinesterase Reactivators/administration & dosage , Nanoparticles/administration & dosage , Pralidoxime Compounds/administration & dosage , Acetylcholinesterase/metabolism , Animals , Antidotes/chemistry , Antidotes/pharmacokinetics , Brain/drug effects , Brain/metabolism , Cholinesterase Reactivators/blood , Cholinesterase Reactivators/chemistry , Cholinesterase Reactivators/pharmacokinetics , Drug Liberation , Female , Humans , Lipids/administration & dosage , Lipids/chemistry , Lipids/pharmacokinetics , Male , Nanoparticles/chemistry , Organophosphorus Compounds/toxicity , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacokinetics , Pralidoxime Compounds/blood , Pralidoxime Compounds/chemistry , Pralidoxime Compounds/pharmacokinetics , Rats, Wistar , Surface PropertiesABSTRACT
Oxime-based acetylcholinesterase reactivators (briefly oximes) regenerate organophosphate-inactivated acetylcholinesterase and restore its function. Poor blood-brain-barrier passage and fast elimination from blood limit their actual use in treatment of patients exposed to organophosphates. Previous in vitro results implicated further testing of cucurbit[7]uril as a delivery vehicle for bisquaternary oximes. The present paper focuses on cell toxicity, in vivo safety and influence of cucurbit[7]uril on oxime pharmacokinetics and pharmacodynamics. Neither the K027 nor the complex caused any cell toxicity, changes in blood biochemistry or hepato- or nephrotoxicity in tested concentrations. The encapsulation of K027 increased and accelerated the blood-brain-barrier penetration. The peripheral oxime exposure also increased, supporting the suggestion that cucurbit[7]uril protects the circulating oxime from rapid renal clearance. Contrary to the comparable in vitro reactivation power of K027 and the encapsulated K027, we failed to confirm this in vivo. In theory, this might result from the non-specific binding of molecules to the cucurbit[7]uril or the interaction of K027 with cucurbit[7]uril being too strong for acetylcholinesterase reactivation. Precise explanation requires additional in silico, in vitro and also in vivo experiments.
Subject(s)
Acetylcholinesterase/blood , Acetylcholinesterase/metabolism , Brain/drug effects , Bridged-Ring Compounds/pharmacokinetics , Cholinesterase Reactivators/pharmacokinetics , Erythrocytes/drug effects , Imidazoles/pharmacokinetics , Oximes/pharmacokinetics , Pyridinium Compounds/pharmacokinetics , A549 Cells , Animals , Brain/enzymology , Bridged-Ring Compounds/administration & dosage , Bridged-Ring Compounds/toxicity , Cell Survival/drug effects , Cholinesterase Reactivators/administration & dosage , Cholinesterase Reactivators/toxicity , Dose-Response Relationship, Drug , Erythrocytes/enzymology , Female , GPI-Linked Proteins/blood , GPI-Linked Proteins/metabolism , Hep G2 Cells , Humans , Imidazoles/administration & dosage , Imidazoles/toxicity , Injections, Intramuscular , Male , Maximum Tolerated Dose , Mice, Inbred ICR , Oximes/administration & dosage , Oximes/toxicity , Pyridinium Compounds/administration & dosage , Pyridinium Compounds/toxicity , Risk Assessment , Tissue DistributionABSTRACT
There is a unique in vivo interplay involving the mechanism of inactivation of acetylcholinesterase (AChE) by toxic organophosphorus (OP) compounds and the restoration of AChE activity by oxime antidotes. OP compounds form covalent adducts to this critical enzyme target and oximes are introduced to directly displace the OP from AChE. For the most part, the in vivo inactivation of AChE leading to neurotoxicity and antidote-based therapeutic reversal of this mechanism are well understood, however, these molecular-level events have not been evaluated by dynamic imaging in living systems at millimeter resolution. A deeper understanding of these critically, time-dependent mechanisms is needed to develop new countermeasures. To address this void and to help accelerate the development of new countermeasures, positron-emission tomography (PET) has been investigated as a unique opportunity to create platform technologies to directly examine the interdependent toxicokinetic/pharmacokinetic and toxicodynamic/pharmacodynamic features of OPs and oximes in real time within live animals. This review will cover two first-in-class PET tracers representing an OP and an oxime antidote, including their preparation, requisite pharmacologic investigations, mechanistic interpretations, biodistribution and imaging.
Subject(s)
Cholinesterase Reactivators/pharmacokinetics , Nerve Agents , Organophosphorus Compounds , Positron-Emission Tomography/methods , Radiopharmaceuticals , Animals , Antidotes/pharmacokinetics , Humans , Nerve Agents/pharmacokinetics , Nerve Agents/toxicity , Organophosphorus Compounds/pharmacokinetics , Organophosphorus Compounds/toxicity , Oximes/pharmacokineticsABSTRACT
AIMS: K117 and K127 are bis-pyridinium aldoximes but K117 is a bis-pyridinium bis-aldoxime while K127 has only one single aldoxime in addition to its amide substituent. Is there any difference in pharmacokinetics in these compounds that otherwise have the same chemical structure? Both K117 and K127 are developed as antidotes in acetylcholinesterase and butyrylcholinesterase poisoning in terrorist attacks or intoxication with other organophosphorous compounds. Their distributions have been scouted in the bodies of rats. MAIN METHODS: White male Wistar rats were intramuscularly injected. The animals were sacrificed, tissue samples were homogenized, and either K117 or K127 concentrations were determined using reversed-phase high-performance liquid chromatography. KEY FINDINGS: Both K117 and K127 were present in all tissues that were analyzed including blood (serum), the brains, cerebrospinal fluid, the eyes, livers, kidneys, lungs and testes. Their pharmacokinetics and body distributions are similar. SIGNIFICANCE: Either K117 or K127 meets the essential requirements for antidotes. Dose dependence and kinetics of their distribution were compared to that of other pyridinium aldoximes.
Subject(s)
Antidotes/pharmacokinetics , Organophosphates/antagonists & inhibitors , Oximes/pharmacokinetics , Pyridinium Compounds/pharmacokinetics , Acetylcholinesterase/chemistry , Animals , Butyrylcholinesterase/chemistry , Chemical Warfare Agents/pharmacokinetics , Cholinesterase Inhibitors/pharmacokinetics , Cholinesterase Reactivators/pharmacokinetics , Oximes/analysis , Pyridinium Compounds/analysis , Rats , Rats, Wistar , Tissue DistributionABSTRACT
The misuse of organophosphate compounds still represents a current threat worldwide. Treatment of poisoning with organophosphates (OPs) remains unsatisfactorily resolved despite the extensive investment in research in academia. There are no universal, effective and centrally-active acetylcholinesterase (AChE) reactivators to countermeasure OP intoxication. One major obstacle is to overcome the blood-brain barrier (BBB). The central compartment is readily accessible by the OPs which are lipophilic bullets that can easily cross the BBB, whereas first-line therapeutics, namely oxime-based AChE reactivators and atropine, do not cross or do so rather slowly. The limitation of oxime-based AChE reactivators can be ascribed to their chemical nature, bearing a positive charge which is essential either for their AChE affinity or their reactivating potency. The aim of this article is to review the methods for targeting the brain by oxime reactivators that have been developed so far. Approaches using prodrugs, lipophilicity enhancement, or sugar-based oximes have been rather unsuccessful. However, other strategies have been more promising, such as the use of nanoparticles or co-administration of the reactivator with efflux transporter inhibitors. Encouraging results have also been associated with intranasal delivery, but research in this field is still at the beginning. Further research of auspicious approaches is inevitable.
Subject(s)
Brain/metabolism , Cholinesterase Reactivators/pharmacokinetics , Oximes/pharmacokinetics , Animals , Biological Transport , Cholinesterase Inhibitors/poisoning , Cholinesterase Reactivators/administration & dosage , Cholinesterase Reactivators/therapeutic use , Humans , Organophosphate Poisoning/drug therapy , Organophosphate Poisoning/metabolism , Oximes/administration & dosage , Oximes/therapeutic useABSTRACT
Organophosphorus nerve agents still represent a serious risk to human health. In the French armed forces, the current emergency treatment against OP intoxications is a fully licensed wet-dry dual-chambered autoinjector (Ineurope ®), that contains pralidoxime methylsulfate (2-PAM) to reactivate inhibited acetylcholinesterase (AChE), atropine sulfate (AS) and avizafone chlorhydrate (AVZ). While this treatment is effective against several of the known nerve agents, it shows little efficacy against the Russian VX (VR), one of the most toxic compounds. HI-6 dimethanesulfonate (HI-6 DMS) is an oxime able to reactivate in vitro and in vivo VR-inhibited AChE. To confirm the superiority of HI-6 DMS towards 2-PAM prior to licensing, we compared the two 3-drug-combinations (HI-6 vs 2-PAM, 33 and 18 mg/kg respectively, equimolar doses; AS/AVZ 0.25/0.175 mg/kg respectively) in VR-poisoned cynomolgus macaques, the model required by the French drug regulatory agency. In parallel we performed HI-6 pharmacokinetics analysis using a one compartment model. A better efficacy of the HI-6 DMS combination was clearly observed: up to 5 LD50 of VR (i.m.), a single administration of the HI-6 DMS combination, shortly after the onset of clinical signs, prevented death of the four intoxicated animals. Conversely 2-PAM only prevented death in one out of three subjects exposed to the same amount of VR. As expected with V agents, reinhibition of blood AChE was observed but without any apparent impact on the clinical recovery of the animals. A single administration of the HI-6 DMS combination was still but partially effective at 15 LD50 of VR, allowing a 50% survival rate.
Subject(s)
Cholinesterase Inhibitors/poisoning , Cholinesterase Reactivators/therapeutic use , Nerve Agents/poisoning , Organothiophosphorus Compounds/poisoning , Pralidoxime Compounds/therapeutic use , Animals , Blood Gas Analysis , Body Temperature/drug effects , Cholinesterase Reactivators/pharmacokinetics , Cholinesterases/blood , Heart Rate/drug effects , Lethal Dose 50 , Macaca fascicularis , Male , Motor Activity/drug effects , Mydriasis/chemically induced , Mydriasis/pathology , Oximes/pharmacokinetics , Oximes/therapeutic use , Pralidoxime Compounds/pharmacokinetics , Pyridinium Compounds/pharmacokinetics , Pyridinium Compounds/therapeutic use , Survival RateABSTRACT
The efficacy and pharmacokinetics of the aqueous co-formulation contents of the Trobigard™ (atropine sulfate, obidoxime chloride) auto-injector were evaluated in a sarin exposed guinea pig model. Two subcutaneous (sc) sarin challenge doses were evaluated in guinea pigs instrumented with brain and heart electrodes for electroencephalogram (EEG) and electrocardiogram (ECG). Sarin challenge doses were chosen to reflect exposure subclasses with sublethal (moderate to severe clinical signs) and lethal consequences. The level of protection of intramuscular human equivalent doses of the co-formulation was defined by (1) the mitigation of signs and symptoms at a sublethal level and (2) the increase of survival time at the supralethal sarin dose levels. Pharmacokinetics of both atropine sulfate and obidoxime were proportional at 1 and 3 human equivalent doses, and only a small increase in heart rate was observed briefly as a side effect. At both sarin challenge doses, 54⯵g/kg and 84⯵g/kg, the co-formulation treatment was effective against sarin-induced effects. Survival rates were improved at both sarin challenge levels, whereas clinical signs and changes in EEG activity could not in all cases be effectively mitigated, in particular at the supralethal sarin challenge dose level. Reactivation of sarin inhibited cholinesterase was observed in blood, and higher brain cholinesterase activity levels were associated with a better clinical condition of the co-formulation treated animals. Although the results cannot be directly extrapolated to the human situation, pharmacokinetics and the effects over time related to plasma levels of therapeutics in a freely moving guinea pig could aid translational models and possibly improve prediction of efficacy in humans.
Subject(s)
Atropine/pharmacology , Obidoxime Chloride/pharmacology , Sarin/antagonists & inhibitors , Animals , Atropine/administration & dosage , Atropine/chemistry , Atropine/pharmacokinetics , Cholinesterase Reactivators/administration & dosage , Cholinesterase Reactivators/chemistry , Cholinesterase Reactivators/pharmacokinetics , Cholinesterase Reactivators/pharmacology , Cholinesterases/metabolism , Dose-Response Relationship, Drug , Drug Compounding , Electroencephalography , Guinea Pigs , Injections, Subcutaneous , Male , Obidoxime Chloride/administration & dosage , Obidoxime Chloride/chemistry , Obidoxime Chloride/pharmacokinetics , Sarin/pharmacology , Structure-Activity Relationship , Survival RateABSTRACT
Oxime reactivators are critical antidotes after organophosphate pesticide or nerve agent poisoning, directly restoring the function of inhibited acetylcholinesterase. In the continuing search for more broad-spectrum acetylcholinesterase reactivators, this study evaluated one of the leading next-generation oxime reactivators: methoxime, (1,1'-trimethylene bis[4-(hydroxyimino)methyl]pyridinium dichloride (MMB-4). The pharmacokinetics of both salts of MMB-4 (dichloride [2Cl] and dimethanesulphonate [DMS]) were characterized across a range of relevant doses (19, 58, and 116 µmol/kg, intramuscular) in a nonhuman primate model (male African green monkeys), and only subtle differences were observed between the salts. Additionally, the behavioral and cardiovascular safety of these MMB-4 salts was compared directly to other available oximes (HI-6 2Cl, HI-6 DMS, and pyridine-2-aldoxime chloride (2-PAM Cl)) at comparable projected doses. Automated operant behavioral tests were used to examine attention, motivation, visual discrimination, concept execution, and fine motor coordination after high doses of all oxime salts, and of all oximes studied, only the highest dose of 2-PAM Cl (447 µmol/kg) disrupted behavioral performance. Likewise, the effects of a range of doses of MMB-4 2Cl or DMS, HI-6 2Cl or DMS, or 2-PAM Cl on cardiovascular parameters were measured in African green monkeys implanted with telemetry devices. Only a small transient decrease in pulse pressure was observed following administration of the highest dose of MMB-4 DMS (116 µmol/kg). Thus, MMB-4 salts, up to the 9× equivalent of a projected autoinjector dose in humans, did not produce behavioral or cardiovascular toxicity in African green monkeys in the current study, and the pharmacokinetic parameters were orderly and predictable.
Subject(s)
Antidotes , Cholinesterase Reactivators , Oximes , Animals , Antidotes/pharmacokinetics , Antidotes/toxicity , Behavior, Animal/drug effects , Blood Pressure/drug effects , Chlorocebus aethiops , Choice Behavior/drug effects , Cholinesterase Reactivators/blood , Cholinesterase Reactivators/pharmacokinetics , Cholinesterase Reactivators/toxicity , Heart Rate/drug effects , Male , Oximes/blood , Oximes/pharmacokinetics , Oximes/toxicityABSTRACT
Post-exposure nerve agent treatment usually includes administration of an oxime, which acts to restore function of the enzyme acetylcholinesterase (AChE). For immediate treatment of military personnel, this is usually administered with an autoinjector device, or devices containing the oxime such as pralidoxime, atropine and diazepam. In addition to the autoinjector, it is likely that personnel exposed to nerve agents, particularly by the percutaneous route, will require further treatment at medical facilities. As such, there is a need to understand the relationship between dose rate, plasma concentration, reactivation of AChE activity and efficacy, to provide supporting evidence for oxime infusions in nerve agent poisoning. Here, it has been demonstrated that intravenous infusion of HI-6, in combination with atropine, is efficacious against a percutaneous VX challenge in the conscious male Dunkin-Hartley guinea-pig. Inclusion of HI-6, in addition to atropine in the treatment, improved survival when compared to atropine alone. Additionally, erythrocyte AChE activity following poisoning was found to be dose dependent, with an increased dose rate of HI-6 (0.48mg/kg/min) resulting in increased AChE activity. As far as we are aware, this is the first study to correlate the pharmacokinetic profile of HI-6 with both its pharmacodynamic action of reactivating nerve agent inhibited AChE and with its efficacy against a persistent nerve agent exposure challenge in the same conscious animal.
Subject(s)
Chemical Warfare Agents/poisoning , Cholinesterase Reactivators/therapeutic use , Nerve Agents/poisoning , Organothiophosphorus Compounds/antagonists & inhibitors , Organothiophosphorus Compounds/poisoning , Oximes/therapeutic use , Pyridinium Compounds/therapeutic use , Acetylcholinesterase/blood , Acetylcholinesterase/metabolism , Animals , Atropine/pharmacology , Cholinesterase Reactivators/administration & dosage , Cholinesterase Reactivators/pharmacokinetics , Dose-Response Relationship, Drug , Guinea Pigs , Infusions, Intravenous , Male , Muscarinic Antagonists/pharmacology , Organothiophosphorus Compounds/administration & dosage , Oximes/administration & dosage , Oximes/pharmacokinetics , Pyridinium Compounds/administration & dosage , Pyridinium Compounds/pharmacokinetics , Survival AnalysisABSTRACT
Fatalities from organophosphate (OP) insecticide result from both occupational and deliberate exposure; significantly impacting human health. Like nerve agents, insecticides are neurotoxins which target and inhibit acetylcholinesterases (AChE) in central and peripheral synapses in the cholinergic nervous system. Post-exposure therapeutic countermeasures generally include administration of atropine with a pyridinium aldoxime e.g. pralidoxime, to reactivate the OP-inhibited AChE. However, commonly used oximes inefficiently cross the bloodbrain barrier and are rapidly cleared and their benefit is debated. Recent findings have demonstrated the ability of a novel zwitterionic, centrally acting, brain penetrating oxime (RS194B) to reverse severe symptoms and rapidly reactivate sarin-inhibited AChE in macaques, but it has not been tested following OP pesticide poisoning. In the present study, the symptoms following a lethal dose of inhaled paraoxon (100ug/kg), were shown to mimic those in insecticide poisoned individuals and were also rapidly reversed in macaques by post-exposure IM administration of 80mg/kg of RS194B. This occurred with a concomitant reactivation of AChE to 40-100% in<1hr and BChE (40% in 8h). These findings will be used to develop a macaque model with RS194B as a post-exposure treatment for insecticide poisoning and generate efficacy data for approval under the FDA Animal rule.
Subject(s)
Acetamides/therapeutic use , Cholinesterase Inhibitors/toxicity , Cholinesterase Reactivators/therapeutic use , Insecticides/toxicity , Oximes/therapeutic use , Paraoxon/antagonists & inhibitors , Paraoxon/toxicity , Acetamides/pharmacokinetics , Acetylcholinesterase/metabolism , Aerosols , Animals , Butyrylcholinesterase/metabolism , Chemical Warfare Agents/poisoning , Cholinesterase Inhibitors/pharmacokinetics , Cholinesterase Reactivators/pharmacokinetics , Female , Inhalation Exposure , Insecticides/pharmacokinetics , Macaca mulatta , Organophosphate Poisoning/drug therapy , Oximes/pharmacokinetics , Paraoxon/pharmacokineticsABSTRACT
Acetylcholinesterase (AChE) inhibited by the organophosphorus nerve (OP) agent soman underlies a spontaneous and extremely rapid dealkylation ("aging") reaction which prevents reactivation by oximes. However, in vivo studies in various, soman poisoned animal species showed a therapeutic effect of oximes, with the exact mechanism of this effect remaining still unclear. In order to get more insight and a basis for the extrapolation of animal data to humans, we applied a dynamic in vitro model with continuous online determination of AChE activity. This model allows to simulate the in vivo toxico- and pharmacokinetics between human and guinea pig AChE with soman and the oximes HI-6 and MMB-4 in order to unravel the species dependent kinetic interactions. It turned out that only HI-6 was able to slow down the ongoing inhibition of human AChE by soman without preventing final complete inhibition of the enzyme. Continuous perfusion of AChE with soman and simultaneous or delayed (8, 15 or 40min) oxime perfusion did not result in a relevant reactivation of AChE (less than 2%). In conclusion, the results of the present study indicate a negligible reactivation of soman-inhibited AChE by oximes at conditions simulating the in vivo poisoning by soman. The observed therapeutic effect of oximes in soman poisoned animals in vivo must be attributed to alternative mechanisms which may not be relevant in humans.
Subject(s)
Antidotes/pharmacology , Chemical Warfare Agents/poisoning , Cholinesterase Inhibitors/poisoning , Cholinesterase Reactivators/pharmacology , Oximes/pharmacology , Pyridinium Compounds/pharmacology , Soman/antagonists & inhibitors , Soman/poisoning , Acetylcholinesterase/metabolism , Animals , Antidotes/pharmacokinetics , Cholinesterase Reactivators/pharmacokinetics , Erythrocyte Membrane/drug effects , Erythrocytes/drug effects , Guinea Pigs , Humans , Kinetics , Oximes/pharmacokinetics , Pyridinium Compounds/pharmacokinetics , Species SpecificityABSTRACT
Recently, a new class of reactivators of chemical warfare agent inhibited acetylcholinesterase (AChE) with promising in vitro potential was developed by the covalent linkage of an oxime nucleophile and a peripheral site ligand. However, the complexity of these molecular structures thwarts their accessibility. We report the compatibility of various oxime-based compounds with the use of the Ugi multicomponent reaction in which four readily accessible building blocks are mixed together to form a product that links a reactivating unit and a potential peripheral site ligand. A small library of imidazole and imidazolium reactivators was successfully synthesized using this method. Some of these compounds showed a promising ability to reactivate AChE inhibited by various types of CWA in vitro. Molecular modeling was used to understand differences in reactivation potential between these compounds. Four compounds were evaluated in vivo using sarin-exposed rats. One of the reactivators showed improved in vivo efficacy compared to the current antidote pralidoxime (2-PAM).
Subject(s)
Acetylcholinesterase/metabolism , Cholinesterase Reactivators/chemical synthesis , Cholinesterase Reactivators/pharmacology , Animals , Brain/metabolism , Cholinesterase Inhibitors/adverse effects , Cholinesterase Reactivators/administration & dosage , Cholinesterase Reactivators/pharmacokinetics , Humans , Imidazoles/administration & dosage , Imidazoles/chemical synthesis , Imidazoles/pharmacokinetics , Imidazoles/pharmacology , Kinetics , Male , Models, Molecular , Molecular Docking Simulation , Nerve Agents/adverse effects , Oximes/administration & dosage , Oximes/chemical synthesis , Oximes/pharmacokinetics , Oximes/pharmacology , Pralidoxime Compounds/pharmacology , Rats, Wistar , Sarin/adverse effectsABSTRACT
Organophosphorus-based (OP) nerve agents represent some of the most toxic substances known to mankind. The current standard of care for exposure has changed very little in the past decades, and relies on a combination of atropine to block receptor activity and oxime-type acetylcholinesterase (AChE) reactivators to reverse the OP binding to AChE. Although these oximes can block the effects of nerve agents, their overall efficacy is reduced by their limited capacity to cross the blood-brain barrier (BBB). RS194B, a new oxime developed by Radic et al. (J. Biol. Chem., 2012) has shown promise for enhanced ability to cross the BBB. To fully assess the potential of this compound as an effective treatment for nerve agent poisoning, a comprehensive evaluation of its pharmacokinetic (PK) and biodistribution profiles was performed using both intravenous and intramuscular exposure routes. The ultra-sensitive technique of accelerator mass spectrometry was used to quantify the compound's PK profile, tissue distribution, and brain/plasma ratio at four dose concentrations in guinea pigs. PK analysis revealed a rapid distribution of the oxime with a plasma t1/2 of â¼1 h. Kidney and liver had the highest concentrations per gram of tissue followed by lung, spleen, heart and brain for all dose concentrations tested. The Cmax in the brain ranged between 0.03 and 0.18% of the administered dose, and the brain-to-plasma ratio ranged from 0.04 at the 10 mg/kg dose to 0.18 at the 200 mg/kg dose demonstrating dose dependent differences in brain and plasma concentrations. In vitro studies show that both passive diffusion and active transport contribute little to RS194B traversal of the BBB. These results indicate that biodistribution is widespread, but very low quantities accumulate in the guinea pig brain, indicating this compound may not be suitable as a centrally active reactivator.
Subject(s)
Acetamides/pharmacokinetics , Cholinesterase Reactivators/pharmacokinetics , Oximes/pharmacokinetics , Acetamides/administration & dosage , Acetylcholinesterase/metabolism , Animals , Blood-Brain Barrier/metabolism , Cholinesterase Reactivators/administration & dosage , Guinea Pigs , Kidney/metabolism , Male , Oximes/administration & dosage , Oximes/metabolism , Tissue DistributionABSTRACT
Standard treatment of organophosphorus compounds (OPs) poisoning includes administration of an anti-muscarinic (atropine), anticonvulsive (diazepam) and acetylcholinesterase reactivator (oxime). From a wide group of newly synthesized oximes, oxime K027 and oxime K203 seem to be perspective compounds in some specific OPs intoxication. The available in vitro and in vivo preclinical data indicate that both oximes may be considered for potential human use. The main aim of this study was to establish plasmatic concentration curves of both oximes after intramuscular (i.m.) and intragastric (i.g.) application with subsequent pharmacokinetic analysis and study distribution after (i.m.) application on a non-rodent animal model (experimental pigs; 1500mg/animal). According to the results, both oximes had similar Cmax (K027: 106±19µg/mL and K203: 111±8µg/mL) in Tmax 19±5min, respectively, in 22±3min. Bioavailability of oxime K027 calculated as AUCtotal (8389±1024minµg/mL) was halved compared to oxime K203 (16938±795minµg/mL). The highest concentration from peripheral tissues was found in the kidney and lung, but the brain concentrations stay very low, the plasma/brain ratio being approximately 1%. The applied doses were derived from the recommendation where it is possible to use three autoinjectors to save human life. The results provide us with knowledge about the pharmacokinetics and distribution of these new oximes and may help us to better estimate the human pharmacokinetic profile.
Subject(s)
Acetylcholinesterase/metabolism , Cholinesterase Reactivators/pharmacokinetics , Oximes/pharmacokinetics , Pyridinium Compounds/pharmacokinetics , Administration, Oral , Animals , Area Under Curve , Cholinesterase Reactivators/administration & dosage , Cholinesterase Reactivators/blood , Chromatography, High Pressure Liquid , Female , Injections, Intramuscular , Organ Specificity , Oximes/administration & dosage , Oximes/blood , Pyridinium Compounds/administration & dosage , Pyridinium Compounds/blood , Sus scrofa , Tissue DistributionABSTRACT
BACKGROUND: Current therapies for organophosphate poisoning involve administration of oximes, such as pralidoxime (2-PAM), that reactivate the enzyme acetylcholinesterase. Studies in animal models have shown a low concentration in the brain following systemic injection. METHODS: To assess 2-PAM transport, we studied transwell permeability in three Madin-Darby canine kidney (MDCKII) cell lines and stem cell-derived human brain microvascular endothelial cells (BC1-hBMECs). To determine whether 2-PAM is a substrate for common brain efflux pumps, experiments were performed in the MDCKII-MDR1 cell line, transfected to overexpress the P-gp efflux pump, and the MDCKII-FLuc-ABCG2 cell line, transfected to overexpress the BCRP efflux pump. To determine how transcellular transport influences enzyme reactivation, we developed a modified transwell assay where the inhibited acetylcholinesterase enzyme, substrate, and reporter are introduced into the basolateral chamber. Enzymatic activity was inhibited using paraoxon and parathion. RESULTS: The permeability of 2-PAM is about 2 × 10(-6) cm s(-1) in MDCK cells and about 1 × 10(-6) cm s(-1) in BC1-hBMECs. Permeability is not influenced by pre-treatment with atropine. In addition, 2-PAM is not a substrate for the P-gp or BCRP efflux pumps. CONCLUSIONS: The low permeability explains poor brain penetration of 2-PAM and therefore the slow enzyme reactivation. This elucidates one of the reasons for the necessity of sustained intravascular (IV) infusion in response to organophosphate poisoning.
Subject(s)
Acetylcholinesterase/metabolism , Biological Transport/physiology , Cholinesterase Reactivators/pharmacokinetics , Endothelial Cells/drug effects , Endothelial Cells/enzymology , Pralidoxime Compounds/pharmacokinetics , Animals , Biological Transport/drug effects , Brain/blood supply , Brain/drug effects , Brain/enzymology , Capillary Permeability/drug effects , Capillary Permeability/physiology , Cell Line , Cholinesterase Inhibitors/pharmacology , Cholinesterase Reactivators/pharmacology , Dogs , Dose-Response Relationship, Drug , Drug Interactions , Fluorescent Dyes/pharmacokinetics , Humans , Microvessels/drug effects , Microvessels/enzymology , Paraoxon/pharmacology , Parathion/pharmacology , Pralidoxime Compounds/pharmacology , Rhodamine 123/pharmacokineticsABSTRACT
INTRODUCTION: The absorption, distribution, metabolism, excretion and toxicity (ADME(T)) of oxime reactivators have been assessed with respect to their polarity, a fundamental requirement for their specific mechanism of action in the intoxication with organophosphorous compounds. The limitations of the therapeutic outcome have been associated not only with the severity of intoxication and to particularities of the toxicants, but also to the reduced lipophilicity and consequent restricted permeability across biological barriers. AREAS COVERED: This article inventories the plethora of mnemotic rules developed throughout the years for defining chemical spaces where drugs share one or more structural and ADME(T) characteristics. Their applicability to oxime is analyzed, especially in relation to intestinal absorption and brain distribution. Other aspects of oximes for antidotal outcome are also reviewed. EXPERT OPINION: The drugability rules are not applicable to oxime reactivators, because the increase in lipophicity and consequent improved permeability across biological barrier comes together with amplified (neuro)toxicity and reduced reactivating capacity. The available data suggest a high solubility and reduced metabolism, assigning the quaternary oximes to the fourth class of Biopharmaceutical Classification Systems. Reliance upon oral absorption data for designing safe centrally acting oximes can be of potential value, with adequate characterization of uptake-influx transporters interplay.
Subject(s)
Antidotes/administration & dosage , Organophosphate Poisoning/drug therapy , Oximes/administration & dosage , Animals , Antidotes/chemistry , Antidotes/pharmacokinetics , Brain/metabolism , Cholinesterase Reactivators/administration & dosage , Cholinesterase Reactivators/chemistry , Cholinesterase Reactivators/pharmacokinetics , Drug Design , Humans , Oximes/chemistry , Oximes/pharmacokinetics , Permeability , Solubility , Tissue DistributionABSTRACT
Despite extensive research for decades no effective broad-spectrum oxime for the treatment of poisoning by a broad range of nerve agents is available. Previous in vitro and in vivo data indicate that the combination of in service oximes could be beneficial. To investigate the ability of obidoxime, HI-6 and the combination of both oximes to reactivate inhibited human AChE in the presence of sarin, cyclosarin or tabun we adopted a dynamic in vitro model with real-time and continuous determination of AChE activity to simulate inhalation nerve agent exposure and intramuscular oxime administration. The major findings of this kinetic study are that the extent and velocity of reactivation is dependent on the nerve agent and the oxime-specific reactivating potency. The oxime-induced reactivation of inhibited human AChE in the presence of nerve agents is markedly impaired and the combination of obidoxime and HI-6 had no additive effect but could broaden the spectrum. In conclusion, these data indicate that a combination of obidoxime and HI-6 would be beneficial for the treatment of poisoning by a broad spectrum of nerve agents and could present an interim solution until more effective and broad-spectrum reactivators are available.